Cover Image
市場調查報告書

A型流感病毒 H3N2亞型感染疾病:開發中產品分析

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 369078
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
A型流感病毒 H3N2亞型感染疾病:開發中產品分析 Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 113 Pages
簡介

H3N2感染疾病是由變種的流感病毒H3N2病毒所引起。症狀有咳嗽,喉嚨痛,鼻涕·鼻塞,發冷,噁心,嘔吐,或是腹瀉等。危險因子有年齡,氣喘和糖尿病,心臟病,免疫系統衰弱,神經系統或神經發達症狀等慢性內科疾病。治療有使用抗病毒藥物和抗生素。

本報告提供治療A型流感病毒 H3N2亞型感染疾病所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

簡介

  • 調查範圍

A型流感病毒 H3N2亞型感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

  • AbbVie Inc
  • AIMM Therapeutics B.V.
  • Aphios Corporation
  • Celltrion, Inc.
  • FluGen, Inc.
  • Glide Pharmaceutical Technologies Limited
  • ILiAD Biotechnologies, LLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medicago Inc.
  • MedImmune, LLC
  • Mucosis B.V.
  • NanoViricides, Inc.
  • OPKO Health, Inc.
  • Sarepta Therapeutics, Inc.
  • 武田藥品工業
  • VBI Vaccines Inc.
  • Visterra, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9089IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 5, 16 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 4 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Influenza A Virus, H3N2 Subtype Infections - Overview
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • AIMM Therapeutics BV
    • Aphios Corp
    • BiondVax Pharmaceuticals Ltd
    • Celltrion Inc
    • FluGen Inc
    • Glide Pharmaceutical Technologies Ltd
    • ILiAD Biotechnologies LLC
    • Inovio Pharmaceuticals Inc
    • Johnson & Johnson
    • Medicago Inc
    • MedImmune LLC
    • Mucosis BV
    • NanoViricides Inc
    • Novavax Inc
    • OPKO Health Inc
    • Protein Sciences Corp
    • Sanofi Pasteur SA
    • Sarepta Therapeutics Inc
    • SK Chemicals Co Ltd
    • Takeda Pharmaceutical Company Ltd
    • VBI Vaccines Inc
    • Visterra Inc
    • Zydus Cadila Healthcare Ltd
  • Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
    • APP-0205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APP-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-5075S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-5080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cetylpyridinium chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-8020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-8043 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTP-27 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fluad (quadrivalent) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FluGEM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gamma-Flu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2v] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strain A/H3N2v] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-3872 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBP-607 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-8877 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVINF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Influenza Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNSIA-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radavirsen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REDEE FLU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for RSV and Influenza A Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
  • Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
  • Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't Yet Exist
      • Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
      • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
      • Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics BV, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Protein Sciences Corp, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra Inc, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2017
  • Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top